-
Mashup Score: 2Chimeric antigen receptor and bispecific T‐cell engager therapies in multiple myeloma patients with prior allogeneic transplantation - 5 day(s) ago
An official journal of the British Society for Haematology, the British Journal of Haematology offers high visibility for clinical, basic and translational research.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 18Peeling Back the Layers: Recurrent Talquetamab Skin Toxicity After Supportive Stem Cell Boost in Multiple Myeloma - PubMed - 9 day(s) ago
Bispecific antibodies have meaningfully expanded the therapeutic armentarium in multiple myeloma. Talquetamab is a CD3+ T cell redirecting antibody targeting GPRC5D, which is expressed on multiple myeloma plasma cells as well as in keratinized tissues. Due to the expression pattern, toxicity of talq …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1Significance of the pee-value: relevance of 24-hour urine studies for patients with myeloma - 9 day(s) ago
International Myeloma Working Group (IMWG) response criteria require refrigerated 24-hour urine specimens for most patients. However, given that serum free light chain testing has been shown to out…
Source: www.tandfonline.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2The utility of repeat kidney biopsy in systemic immunoglobulin light chain amyloidosis - PubMed - 15 day(s) ago
Background: The diagnostic utility of repeat kidney biopsy in AL amyloidosis patients in complete (CR) or very good partial hematologic response (VGPR) but with renal organ relapse is not clear.Methods: We present eight patients with AL amyloidosis who had a repeat kidney biopsy perfor …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 5What Are the Benefits of Myeloma Consults and Second Opinions? - Patient Empowerment Network - 15 day(s) ago
What can myeloma consults and second opinions bring to patients? Dr. Ola Landgren shares his perspective on the benefits.
Source: powerfulpatients.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 26Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma - 16 day(s) ago
Amp(1q), HRCA ≥2, high CTC levels, and a longer time to reach first MRD negativity are significant predictors of unsustained MRD negativity.Maintenance treatmen
Source: ashpublications.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 2
Plus, a bone-marrow-transplant revolution, and why fewer college football players are entering the NFL draft.
Source: apple.newsCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 7Program Guide – ASCO Meeting Program Guide - 18 day(s) ago
The 2024 ASCO Annual Meeting is funded through Conquer Cancer®, the ASCO Foundation, by these sponsorship donors. Bristol Myers Squibb Daiichi Sankyo,
Source: meetings.asco.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 7Program Guide – ASCO Meeting Program Guide - 18 day(s) ago
The 2024 ASCO Annual Meeting is funded through Conquer Cancer®, the ASCO Foundation, by these sponsorship donors. Bristol Myers Squibb Daiichi Sankyo,
Source: meetings.asco.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 19Our Journey | Emily Whitehead Foundation - 25 day(s) ago
Emily Whitehead has been in remission since 2012 after receiving CAR T-cell therapy to treat her leukemia.
Source: emilywhiteheadfoundation.orgCategories: General Medicine News, Partners & KOLsTweet
2/ This adds to an earlier collaboration between @MedicalCollege @fredhutch led by @LHammonsMD @AJPortuguese @bhemato about the efficacy of IEC therapy in patients with #MMsm who have been allografted. https://t.co/hXNL0wvWZi